Boost for new cancer therapies

December 14, 2006

Scientists have revealed the critical role a key enzyme plays in helping cells divide in what could prove an important breakthrough for new cancer therapies.

Cells divide to form two identical cells as part of the body's natural development and replenishment processes but when cells divide in an abnormal manner, tumours can develop.

Research has shown that an enzyme called 'Polo kinase' is involved in normal cell division but that it also goes into overdrive in cancer helping cells to multiply in an uncontrolled way.

Clinical trials on drugs that block the actions of Polo kinase started in the United States last year but the complete picture of how the enzyme assisted the cell-division process has not been clear until now.

Writing in the highly respected science journal, Nature, a team of researchers from the Universities of Manchester and Newcastle-upon-Tyne have described a new way in which the enzyme works.

"Enzymes are proteins that speed up or 'catalyse' the body's chemical reactions such as those required for normal cell division," explained Professor Andrew Sharrocks, lead researcher in Manchester's Faculty of Life Sciences.

"As its name suggests, the enzyme we have studied is from a group known as kinase enzymes which use a particular chemical - a phosphate - to catalyse the reactions that lead to cell division.

"Our study has identified a new target protein that uses these phosphate groups to switch on genes and alter the properties of cells.

"When the actions of enzymes like Polo kinase go unchecked, cells divide in an uncontrolled manner to form tumours. However, if we block their activity using chemical inhibitors the cells can no longer divide and the cancer cannot grow and spread."

The identification of a new key step in which Polo kinase functions confirms the choice of this enzyme as a target for anti-cancer drug development and will spur on efforts in this direction.

Indeed, as scientists now have a much greater understanding of the mechanisms involved, it might enable them to either develop more effective drugs or suggest different situations in which the drug can be used.

"Kinase inhibitors are proving to be very effective at killing off rogue cells and trials on patients elsewhere have been promising with fewer toxic effects than current cancer treatments," said Professor Sharrocks.

"Our research on Polo kinase will help with this line of drug development and hopefully produce more effective kinase-blocking chemicals that will one day treat patients with different types of cancer."
-end-


University of Manchester

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.